Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases.

T.R. Jeffry Evans,Eric Van Cutsem,Hans Prenen,Mark R. Middleton,Debashis Sarker,Karin Tunblad,Fredrik Öberg,Thomas Morris,Linda Basse,Elizabeth Ruth Plummer

Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases.

2021

T.R. Jeffry Evans
Eric Van Cutsem
Hans Prenen
Mark R. Middleton
Debashis Sarker
Karin Tunblad
Fredrik Öberg
Thomas Morris
Linda Basse
Elizabeth Ruth Plummer

309Background: MIV-818 is an orally administered troxacitabine (TRX)-based nucleotide prodrug. It is highly metabolized by human hepatocytes, directing high levels of the chain-terminating nucleoti...

Keywords:

phase i study
Troxacitabine
in patient
Hepatocellular carcinoma
Cancer research
Medicine
Prodrug

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations